Neoadjuvant versus adjuvant chemotherapy for resectable malignant pleural mesothelioma: An analysis of the National Cancer Database.

Espinoza-Mercado, Fernando; Berz, David; Borgella, Jerald; Imai, Taryne A.; Soukiasian, Harmik J.

doi:10.1200/jco.2018.36.15_suppl.e20556

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is the major difference from chemotherapy performed prior to surgery, which can only reduce the tumor mass (62). Indeed, the effectiveness of chemotherapy as adjuvant treatment is still an open debate; a recent study highlighted an equivalent risk of death for patients receiving neoadjuvant or adjuvant chemotherapy, thus suggesting no significant difference between the two regimens (63). Accordingly, immunotherapy appears to be a reasonable alternative to chemotherapy and several clinical trials are undergoing to prove the effectiveness of neoadjuvant treatment, some of which are discussed below.…”

Section: Neoadjuvant Therapymentioning

confidence: 99%

Novel Insights Into Mesothelioma Therapy: Emerging Avenues and Future Prospects

et al. 2022

View full text Add to dashboard Cite

Malignant mesothelioma is a rare and aggressive cancer that develops in the thin layer surrounding the mesothelium and is mainly caused by asbestos exposure. Despite improvements in patient prognosis with conventional cancer treatments, such as surgery, chemotherapy, and radiotherapy, there are still no curative treatment modalities for advanced disease. In recent years, new therapeutic avenues have been explored. Improved understanding of the mechanisms underlying the dynamic tumor interaction with the immune system has led to the development of immunotherapeutic approaches. Numerous recent clinical trials have shown a desire to develop more effective treatments that can be used to fight against the disease. Immune checkpoint inhibitors, oncolytic adenoviruses, and their combination represent a promising strategy that can be used to synergistically overcome immunosuppression in the mesothelioma tumor microenvironment. This review provides a synthesized overview of the current state of knowledge on new therapeutic options for mesothelioma with a focus on the results of clinical trials conducted in the field.

show abstract

Section: Neoadjuvant Therapymentioning

confidence: 99%

Novel Insights Into Mesothelioma Therapy: Emerging Avenues and Future Prospects

et al. 2022

View full text Add to dashboard Cite

show abstract

Does delaying surgery following induction chemotherapy compromise survival in patients with mesothelioma?

Wong,

Baiu,

Leipzig

et al. 2023

J Cancer Metastasis Treat

View full text Add to dashboard Cite

Objective: The ideal time interval between induction chemotherapy and surgery and the impact on cancer mortality in patients with mesothelioma remains unclear. Methods: We queried the National Cancer Database (2004-2017) for patients with favorable prognostic factors considered for surgery. Immediate surgery was performed within 3 months following the start of induction chemotherapy, while delayed surgery was defined as surgery performed later than 3 months. We compared both groups to those who did not have an operation despite being surgical candidates, as well as to those who were treated with surgery only. Overall mortality was assessed using Cox proportional hazard models adjusting for covariates. Results: A total of 4,294 patients were included, with the majority of patients undergoing induction chemotherapy followed by no surgery (3,370, 78%). The proportion of patients undergoing both immediate and delayed surgery increased over the last decade, but delayed surgery continued to be more common. There were no significant differences in baseline characteristics between the immediate and delayed surgery groups. Higher comorbidity scores were significantly associated with an increased risk of death on multivariable analysis, but the timing of surgery was not. This held true with a sensitivity analysis using 6 months as the definition of delayed surgery. Conclusions: This study shows that delaying surgery following induction chemotherapy does not compromise overall survival in patients with mesothelioma.

show abstract

Neoadjuvant versus adjuvant chemotherapy for resectable malignant pleural mesothelioma: An analysis of the National Cancer Database.

Cited by 2 publications

References 0 publications

Novel Insights Into Mesothelioma Therapy: Emerging Avenues and Future Prospects

Novel Insights Into Mesothelioma Therapy: Emerging Avenues and Future Prospects

Does delaying surgery following induction chemotherapy compromise survival in patients with mesothelioma?

Contact Info

Product

Resources

About